Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case

By Blake Brittain

(Reuters) – Amgen will launch its biosimilar version of Regeneron’s blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.

The U.S. Court of Appeals for the Federal Circuit rejected Regeneron’s request to temporarily block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia.

Spokespeople for Regeneron did not immediately respond to a request for comment on the decision. Eylea earned Regeneron $5.89 billion in U.S. sales in 2023.

(Reporting by Blake Brittain; Editing by Leslie Adler)